About UCSF Search UCSF UCSF Medical Center

I. Craig Henderson, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Adjunct Professor, Department of Medicine (Hematology/Oncology), UCSF

chenderson@hendersonmd.org

Phone: (415) 674-5148 (voice)
Box 1710, UCSF
San Francisco, CA 94143-1710

View on UCSF Profiles


Education

Grinnell College, Grinnell, IA, A.B., 1963
Columbia University, College of Physicians & Surgeons, New York, NY, M.D., 1970


Professional Experience

  • 1970-1972
    Intern and Resident in Medicine, Presbyterian Hospital, New York, NY
  • 1972-1974
    Research Associate, Viral Leukemia and Lymphoma Branch, NCI, Bethesda
  • 1974-1975
    Clinical Fellow in Medicine, Sydney Farber Cancer Inst., Harvard Medical School (HMS)
  • 1975-1976
    Instructor of Medicine, Sydney Farber Cancer Inst., HMS
  • 1976-1984
    Assistant Professor of Medicine, Dana-Farber Cancer Inst., HMS
  • 1979-1992
    Founder and Director, Breast Evaluation Center, Dana-Farber Cancer Inst., Boston
  • 1981-1982
    Consultant, Cancer Unit, World Health Organization, Geneva, Switzerland
  • 1982-1996
    Breast Core Committee, Cancer and Acute Leukemia Group B (Chairman 1990-1995)
  • 1983-1993
    Subcommittee on Antineoplastic and Immunosuppressive Drugs, Committee on Essential Drugs, World Health Organization (Chairman 1983)
  • 1984-1992
    Associate Professor of Medicine, Dana-Farber Cancer Inst., HMS, Boston
  • 1985-1993
    World Health Organization Expert Advisory Panel on Cancer, Geneva
  • 1985-1995
    Early Breast Cancer Trialists Collaborative Group (Oxford Overview Group) (Chairman 1985-1995)
  • 1987-1990
    United States Congressional Office of Technology Assessment: Working Group on Immuno-Augmentative Therapy
  • 1988-1994
    National Task Force on Breast Cancer Control, American Cancer Society
  • 1989-1992
    Member, Oncologic Drugs Advisory Committee, FDA (Chairman 1990-1992)
  • 1991-1993
    Education Committee, American Society of Clinical Oncology
  • 1992-1995
    Professor of Medicine, University of California San Francisco (UCSF)
  • 1992-1995
    Chief, Division of Oncology, Moffitt-Long-Mt. Zion
  • 1992-1995
    Assoc. Director for Clinical Oncology in Comprehensive Cancer Center, UCSF (Interim)
  • 1992-1996
    Founder, PI, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1996-present
    Steering Committee Member, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1995-present
    Adjunct Professor of Medicine, University of California San Francisco
  • 1995-1999
    CEO and Chairman, SEQUUS Pharmaceuticals, Menlo Park Ca.
  • 1999-present
    Senior Consultant, Alza Corporation, Mountain View, Ca. (Director 1999-2001)
  • 2000-present
    Institute of Medicine Committee on Technologies for the Early Detection of Breast Cancer (Vice Chairman)
  • 2000-present
    Breast Cancer Research Council of the State of California
  • 2001-present
    President and Director, Access Oncology, Inc., New York City, NY

Honors & Awards

  • 1966
    Merck, Sharpe and Dohme International Fellow, Columbia University
  • 1970
    Research Prize, Columbia University Medical Society
  • 1988
    Fellow, American College of Physicians
  • 1987
    Henrietta Banting Memorial Lecturer, Canada
  • 1992
    General Motors Cancer Research Foundation Lecturer, The Royal Marsden
  • 1992
    Bernard L. Schwartz Lecturer, Scripps Memorial Hospitals
  • 1993
    British Oncological Association Lecturer, United Kingdom
  • 1993
    Distinguished Alumnus Award, Grinnell College
  • 1994
    Doctorate of Science, Grinnell College
  • 1996
    Wendell Scott Lecture, American College of Radiology
  • 1997
    Fellow, Royal College of Physicians (Edinburgh)
  • 1999
    Outstanding Industry Leader in Medical Research, California Pacific Medical Center Research Institute
  • 2000
    Millennium Award from Bristol-Myers Squibb Oncology and Susan G. Komen Breast Cancer Foundation

Selected Publications

  1. Henderson IC. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012 Nov; 26(11):1035, 1039.
    View on PubMed
  2. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 1; 17(15):5170-8.
    View on PubMed
  3. Henderson IC. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127.
    View on PubMed
  4. Henderson IC. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62.
    View on PubMed
  5. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-63.
    View on PubMed
  6. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13.
    View on PubMed
  7. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72.
    View on PubMed
  8. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View on PubMed
  9. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
    View on PubMed
  10. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
    View on PubMed
  11. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704.
    View on PubMed
  12. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007 Jul; 7(7):919-43.
    View on PubMed
  13. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View on PubMed
  14. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
    View on PubMed
  15. Henderson IC. Axillary surgery: clinical judgment required. J Clin Oncol. 2006 Jan 20; 24(3):325-6.
    View on PubMed
  16. Kumar AS, Bhatia V, Henderson IC. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005; 7(6):271-5.
    View on PubMed
  17. Henderson IC, Piccart-Gebhart MJ. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer. 2005 Aug; 6(3):206-15.
    View on PubMed
  18. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View on PubMed
  19. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 1; 23(19):4287-97.
    View on PubMed
  20. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI